Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Mai 2015 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA

TORONTO, May 21, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
22. April 2015 13:35 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports Director Election Results

TORONTO, April 22, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
14. April 2015 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces First Quarter 2015 Results

TORONTO, April 14, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
30. März 2015 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, and files an IND for Rexista(TM) Oxycodone XR

TORONTO, March 30, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
23. Februar 2015 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces 2014 Year End Results With a 48% Reduction in Operating Loss

TORONTO, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
02. Februar 2015 08:00 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports the Signing of an Exclusive Licensing and Manufacturing Agreement With Teva Pharmaceuticals USA, Inc. for an Extended Release Oral Drug Product Candidate

TORONTO, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
20. November 2014 07:30 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva

TORONTO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
18. November 2014 07:30 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Appointment of New Chief Financial Officer

TORONTO, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of...
27. Oktober 2014 07:15 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification

TORONTO, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
22. Oktober 2014 17:15 ET | Quelle: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)

TORONTO, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...

Vorherige Seite

Nächste Seite